425 related articles for article (PubMed ID: 18838247)
21. Retinal microenvironment controls resident and infiltrating macrophage function during uveoretinitis.
Robertson MJ; Erwig LP; Liversidge J; Forrester JV; Rees AJ; Dick AD
Invest Ophthalmol Vis Sci; 2002 Jul; 43(7):2250-7. PubMed ID: 12091424
[TBL] [Abstract][Full Text] [Related]
22. Increased Regulatory T Cells in Spleen during Experimental Autoimmune Uveoretinitis.
Sun M; Yang P; Du L; Zhou H; Ren X; Lin X; Kijlstra A
Ocul Immunol Inflamm; 2010 Jan; 18(1):38-43. PubMed ID: 20128648
[TBL] [Abstract][Full Text] [Related]
23. Retinal expression of a neo-self antigen, beta-galactosidase, is not tolerogenic and creates a target for autoimmune uveoretinitis.
Gregerson DS; Torseth JW; McPherson SW; Roberts JP; Shinohara T; Zack DJ
J Immunol; 1999 Jul; 163(2):1073-80. PubMed ID: 10395707
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of experimental autoimmune uveitis in mice treated with FTY720.
Commodaro AG; Peron JP; Lopes CT; Arslanian C; Belfort R; Rizzo LV; Bueno V
Invest Ophthalmol Vis Sci; 2010 May; 51(5):2568-74. PubMed ID: 20019358
[TBL] [Abstract][Full Text] [Related]
25. Differential roles for IFN-gamma and IL-17 in experimental autoimmune uveoretinitis.
Yoshimura T; Sonoda KH; Miyazaki Y; Iwakura Y; Ishibashi T; Yoshimura A; Yoshida H
Int Immunol; 2008 Feb; 20(2):209-14. PubMed ID: 18156624
[TBL] [Abstract][Full Text] [Related]
26. Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis.
Broderick C; Hoek RM; Forrester JV; Liversidge J; Sedgwick JD; Dick AD
Am J Pathol; 2002 Nov; 161(5):1669-77. PubMed ID: 12414514
[TBL] [Abstract][Full Text] [Related]
27. Ultrastructural pathology of experimental autoimmune uveitis. Quantitative evidence of activation and possible high endothelial venule-like changes in retinal vascular endothelium.
McMenamin PG; Forrester JV; Steptoe RJ; Dua HS
Lab Invest; 1992 Jul; 67(1):42-55. PubMed ID: 1625447
[TBL] [Abstract][Full Text] [Related]
28. Mapping immune responses to mRBP-3 1-16 peptide with altered peptide ligands.
Guyver CJ; Copland DA; Calder CJ; Sette A; Sidney J; Dick AD; Nicholson LB
Invest Ophthalmol Vis Sci; 2006 May; 47(5):2027-35. PubMed ID: 16639012
[TBL] [Abstract][Full Text] [Related]
29. Amelioration of experimental autoimmune uveoretinitis (EAU) with an inhibitor of nuclear factor-kappaB (NF-kappaB), pyrrolidine dithiocarbamate.
Kitamei H; Iwabuchi K; Namba K; Yoshida K; Yanagawa Y; Kitaichi N; Kitamura M; Ohno S; Onoé K
J Leukoc Biol; 2006 Jun; 79(6):1193-201. PubMed ID: 16574770
[TBL] [Abstract][Full Text] [Related]
30. The monocyte chemokine receptor CX3CR1 does not play a significant role in the pathogenesis of experimental autoimmune uveoretinitis.
Kezic J; McMenamin PG
Invest Ophthalmol Vis Sci; 2010 Oct; 51(10):5121-7. PubMed ID: 20463325
[TBL] [Abstract][Full Text] [Related]
31. T cell traffic and the inflammatory response in experimental autoimmune uveoretinitis.
Prendergast RA; Iliff CE; Coskuncan NM; Caspi RR; Sartani G; Tarrant TK; Lutty GA; McLeod DS
Invest Ophthalmol Vis Sci; 1998 Apr; 39(5):754-62. PubMed ID: 9538882
[TBL] [Abstract][Full Text] [Related]
32. Dynamics of experimental autoimmune uveoretinitis induced by adoptive transfer of S-antigen-specific T cell line.
Chan CC; Caspi RR; Roberge FG; Nussenblatt RB
Invest Ophthalmol Vis Sci; 1988 Mar; 29(3):411-8. PubMed ID: 3257750
[TBL] [Abstract][Full Text] [Related]
33. A clinical grading system for retinal inflammation in the chronic model of experimental autoimmune uveoretinitis using digital fundus images.
Xu H; Koch P; Chen M; Lau A; Reid DM; Forrester JV
Exp Eye Res; 2008 Oct; 87(4):319-26. PubMed ID: 18634784
[TBL] [Abstract][Full Text] [Related]
34. Adoptive transfer of experimental autoimmune uveoretinitis in rats. Immunopathogenic mechanisms and histologic features.
Mochizuki M; Kuwabara T; McAllister C; Nussenblatt RB; Gery I
Invest Ophthalmol Vis Sci; 1985 Jan; 26(1):1-9. PubMed ID: 3967952
[TBL] [Abstract][Full Text] [Related]
35. Effects of CD8 depletion on retinal soluble antigen induced experimental autoimmune uveoretinitis.
Calder VL; Zhao ZS; Wang Y; Barton K; Lightman SL
Immunology; 1993 Jun; 79(2):255-62. PubMed ID: 8102121
[TBL] [Abstract][Full Text] [Related]
36. Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan.
Okunuki Y; Usui Y; Nagai N; Kezuka T; Ishida S; Takeuchi M; Goto H
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2255-61. PubMed ID: 19136706
[TBL] [Abstract][Full Text] [Related]
37. Suppression of experimental autoimmune uveoretinitis by Anti-IL-17 antibody.
Zhang R; Qian J; Guo J; Yuan YF; Xue K
Curr Eye Res; 2009 Apr; 34(4):297-303. PubMed ID: 19373578
[TBL] [Abstract][Full Text] [Related]
38. Everolimus improves experimental autoimmune uveoretinitis.
Hennig M; Bauer D; Wasmuth S; Busch M; Walscheid K; Thanos S; Heiligenhaus A
Exp Eye Res; 2012 Dec; 105():43-52. PubMed ID: 23059401
[TBL] [Abstract][Full Text] [Related]
39. Caffeic acid phenethyl ester lessens disease symptoms in an experimental autoimmune uveoretinitis mouse model.
Choi JH; Roh KH; Oh H; Park SJ; Ha SM; Kang MS; Lee JH; Jung SY; Song H; Yang JW; Park S
Exp Eye Res; 2015 May; 134():53-62. PubMed ID: 25795054
[TBL] [Abstract][Full Text] [Related]
40. Distribution of OX2 antigen and OX2 receptor within retina.
Dick AD; Broderick C; Forrester JV; Wright GJ
Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):170-6. PubMed ID: 11133863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
